$MRNS
MARINUS PHARMACEUTICALS, INC. Stock $mrns

$mrns Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000155837023003305 Filed on March 09, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$10.38M	$7.162M	$25.48M
YoY Change	-26.83%	371.18%	66.03%
Cost Of Revenue	$206.0K	$292.0K	$1.509M
YoY Change	-82.38%		2.1%
Gross Profit	$10.17M	$6.870M	$23.97M
YoY Change	-21.84%		72.85%
Gross Profit Margin	98.02%	95.92%	94.08%
Selling, General & Admin	$15.20M	$14.66M	$56.85M
YoY Change	29.54%	38.0%	52.49%
% of Gross Profit	149.44%	213.36%	237.16%
Research & Development	$27.93M	$21.42M	$79.91M
YoY Change	55.26%	18.93%	8.69%
% of Gross Profit	274.55%	311.85%	333.4%
Depreciation & Amortization	$157.0K	$82.00K	$418.0K
YoY Change	84.71%	-11.83%	17.75%
% of Gross Profit	1.54%	1.19%	1.74%
Operating Expenses	$43.14M	$36.08M	$136.8M
YoY Change	139.77%	26.0%	86.01%
Operating Profit	-$32.96M	-$29.21M	-$112.8M
YoY Change	97.25%		16.36%
Interest Expense	$4.147M	-$1.946M	$10.67M
YoY Change	145.09%	27.19%	313.32%
% of Operating Profit
Other Income/Expense, Net	$37.00K	-$717.0K	-$2.696M
YoY Change	-103.81%	-232.53%	-510.35%
Pretax Income	-$34.73M	-$32.67M	-$16.43M
YoY Change	79.38%	15.44%	-83.37%
Income Tax		$1.637M	$3.389M
% Of Pretax Income
Net Earnings	-$34.70M	-$33.98M	-$19.80M
YoY Change	79.23%	20.04%	-79.95%
Net Earnings / Revenue	-334.3%	-474.39%	-77.71%
Basic Earnings Per Share	-$0.67		-$0.51
Diluted Earnings Per Share	-$0.67	-$0.75	-$0.51
COMMON SHARES
Basic Shares Outstanding	49.67M	37.20M	39.07M
Diluted Shares Outstanding	51.77M		39.07M

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$199.2M	$240.6M	$240.6M
YoY Change	57.7%	95.69%	95.69%
Cash & Equivalents	$146.9M	$240.6M	$240.6M
Short-Term Investments	$52.30M
Other Short-Term Assets	$9.064M	$5.402M	$5.402M
YoY Change	44.72%	-2.93%	-2.93%
Inventory	$37.00K	$77.00K	$77.00K
Prepaid Expenses
Receivables	$11.69M	$6.348M	$6.348M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$220.0M	$252.4M	$252.4M
YoY Change	62.87%	91.66%	91.66%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.037M	$4.236M	$5.536M
YoY Change	35.06%	69.51%	31.84%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.785M	$2.904M	$1.604M
YoY Change	1.27%	9.05%	66.56%
Total Long-Term Assets	$6.822M	$7.140M	$7.140M
YoY Change	18.87%	38.32%	38.32%
TOTAL ASSETS
Total Short-Term Assets	$220.0M	$252.4M	$252.4M
Total Long-Term Assets	$6.822M	$7.140M	$7.140M
Total Assets	$226.8M	$259.5M	$259.5M
YoY Change	61.08%	89.65%	89.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.466M	$4.461M	$4.461M
YoY Change	-4.39%	42.71%	42.71%
Accrued Expenses	$15.73M	$19.54M	$19.54M
YoY Change	5.8%	20.54%	20.54%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$21.51M	$25.02M	$25.02M
YoY Change	10.12%	-38.33%	-38.33%
LONG-TERM LIABILITIES
Long-Term Debt	$71.50M	$71.02M	$71.02M
YoY Change	2.25%	74.03%	74.03%
Other Long-Term Liabilities	$48.72M	$47.48M	$47.48M
YoY Change	345.26%	2299.34%	2299.34%
Total Long-Term Liabilities	$120.2M	$118.5M	$118.5M
YoY Change	48.66%	176.95%	176.95%
TOTAL LIABILITIES
Total Short-Term Liabilities	$21.51M	$25.02M	$25.02M
Total Long-Term Liabilities	$120.2M	$118.5M	$118.5M
Total Liabilities	$141.7M	$143.5M	$143.5M
YoY Change	41.16%	72.18%	72.18%
SHAREHOLDERS EQUITY
Retained Earnings	-$465.3M	-$430.5M
YoY Change	8.18%	4.82%
Common Stock	$50.00K	$50.00K
YoY Change	35.14%	35.14%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$85.09M	$116.0M	$116.0M
YoY Change
Total Liabilities & Shareholders Equity	$226.8M	$259.5M	$259.5M
YoY Change	61.08%	89.65%	89.65%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$34.70M	-$33.98M	-$19.80M
YoY Change	79.23%	20.04%	-79.95%
Depreciation, Depletion And Amortization	$157.0K	$82.00K	$418.0K
YoY Change	84.71%	-11.83%	17.75%
Cash From Operating Activities	-$41.48M	-$21.91M	-$112.9M
YoY Change	49.98%	0.75%	103.48%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$92.00K	$1.774M
YoY Change	-100.0%	-112.76%	-161.41%
Acquisitions
YoY Change
Other Investing Activities	-$52.00M	$171.0K	$107.5M
YoY Change			7196.2%
Cash From Investing Activities	-$52.00M	$79.00K	$105.8M
YoY Change	60359.3%	-110.96%	-7575.05%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-174.0K	94.14M	124.7M
YoY Change	-100.56%	31595.96%	201.96%
NET CHANGE
Cash From Operating Activities	-41.48M	-21.91M	-112.9M
Cash From Investing Activities	-52.00M	79.00K	105.8M
Cash From Financing Activities	-174.0K	94.14M	124.7M
Net Change In Cash	-93.65M	72.30M	117.6M
YoY Change	-2860.82%	-426.07%	-854.87%
FREE CASH FLOW
Cash From Operating Activities	-$41.48M	-$21.91M	-$112.9M
Capital Expenditures	$0.00	$92.00K	$1.774M
Free Cash Flow	-$41.48M	-$22.01M	-$114.7M
YoY Change	50.45%	4.65%	118.03%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	39072599
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36697171
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	39072599
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36697171
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001267813
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherAccruedLiabilitiesNoncurrent
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.69
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2663000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2904000
CY2021Q4	us-gaap	Operating Lease Liability Statement Of Financial Position Extensible List OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2022#OtherAccruedLiabilitiesNoncurrent
CY2022Q4	us-gaap	Operating Lease Liability Statement Of Financial Position Extensible List OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2022#OtherAccruedLiabilitiesNoncurrent
CY2022Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue
CY2021Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.51
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.69
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.51
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherAccruedLiabilitiesNoncurrent
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-36576
CY2022	dei	Entity Registrant Name EntityRegistrantName	Marinus Pharmaceuticals, Inc.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-0198082
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	5 Radnor Corporate Center, Suite 500
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	100 Matsonford Road
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Radnor
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	PA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	19087
CY2022	dei	City Area Code CityAreaCode	484
CY2022	dei	Local Phone Number LocalPhoneNumber	801-4670
CY2022	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2022	dei	Trading Symbol TradingSymbol	MRNS
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	179039833
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	49665117
CY2022	dei	Auditor Firm AuditorFirmId	42
CY2022	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2022	dei	Auditor Location AuditorLocation	Philadelphia, Pennsylvania
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	240551000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	122927000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6348000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2629000
CY2022Q4	us-gaap	Inventory Net InventoryNet	77000
CY2021Q4	mrns	Contract With Customer Asset Liability Net ContractWithCustomerAssetLiabilityNet	557000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5402000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5565000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	252378000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	131678000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4236000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2499000
CY2022Q4	us-gaap	Assets Assets	259518000
CY2021Q4	us-gaap	Assets Assets	136840000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4461000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3126000
CY2021Q4	mrns	Upfront Payment Refund Liability UpfrontPaymentRefundLiability	21233000
CY2022Q4	mrns	Revenue Interest Financing Payable Current RevenueInterestFinancingPayableCurrent	1020000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	19536000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	16207000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	25017000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	40566000
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	71018000
CY2021Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	40809000
CY2022Q4	mrns	Revenue Interest Financing Payable Net Of Deferred Offering Costs Noncurrent RevenueInterestFinancingPayableNetOfDeferredOfferingCostsNoncurrent	29857000
CY2022Q4	mrns	Contract With Customer Contract Liability Net Of Contract Asset ContractWithCustomerContractLiabilityNetOfContractAsset	16285000
CY2022Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	1341000
CY2021Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	1979000
CY2022Q4	us-gaap	Liabilities Liabilities	143518000
CY2021Q4	us-gaap	Liabilities Liabilities	83354000
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	4043000
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	4302000
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	49650074
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	49642767
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	36797561
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	36790254
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	50000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	37000
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	542428000
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	459852000
CY2021Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	7307
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	7307
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-430521000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-410705000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	116000000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	53486000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	259518000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	136840000
CY2022	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	6935000
CY2021	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	6358000
CY2022	us-gaap	Revenues Revenues	25478000
CY2021	us-gaap	Revenues Revenues	15345000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	79912000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	73520000
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	56845000
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	37278000
CY2022	mrns	Cost Of License Fees CostOfLicenseFees	1169000
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	138266000
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	112276000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-112788000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-96931000
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	2354000
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	80000
CY2022	us-gaap	Interest Expense InterestExpense	10672000
CY2021	us-gaap	Interest Expense InterestExpense	2582000
CY2022	mrns	Gain Loss On Sale Of Priority Review Voucher Net GainLossOnSaleOfPriorityReviewVoucherNet	107375000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2696000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	657000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-16427000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-98776000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3389000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-19816000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-98776000
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-19816000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-98776000
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.51
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.69
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39072599
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36697171
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	137199000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	13867000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1199000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	3000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-98776000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	53486000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	14890000
CY2022	mrns	Issuance Of Common Stock And Prefunded Warrants IssuanceOfCommonStockAndPrefundedWarrants	64477000
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1794000
CY2022	mrns	Stock Issued During Period Value Equity Distribution Agreement StockIssuedDuringPeriodValueEquityDistributionAgreement	1169000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-19816000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	116000000
CY2022	us-gaap	Profit Loss ProfitLoss	-19816000
CY2021	us-gaap	Profit Loss ProfitLoss	-98776000
CY2022	mrns	Gain Loss On Sale Of Priority Review Voucher Net GainLossOnSaleOfPriorityReviewVoucherNet	107375000
CY2022	us-gaap	Depreciation Depreciation	418000
CY2021	us-gaap	Depreciation Depreciation	355000
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1663000
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	549000
CY2022	mrns	Accretion Of Revenue Interest Financing Debt AccretionOfRevenueInterestFinancingDebt	956000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	14890000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	13867000
CY2022	mrns	Increase Decrease Amortization Of Net Contract Asset Liability IncreaseDecreaseAmortizationOfNetContractAssetLiability	1052000
CY2021	mrns	Increase Decrease Amortization Of Net Contract Asset Liability IncreaseDecreaseAmortizationOfNetContractAssetLiability	105000
CY2022	mrns	Non Cash Operating Lease Expense Operating Activities NonCashOperatingLeaseExpenseOperatingActivities	251000
CY2021	mrns	Non Cash Operating Lease Expense Operating Activities NonCashOperatingLeaseExpenseOperatingActivities	312000
CY2022	mrns	Interest Expense Income On Lease Liabilities InterestExpenseIncomeOnLeaseLiabilities	344000
CY2021	mrns	Interest Expense Income On Lease Liabilities InterestExpenseIncomeOnLeaseLiabilities	309000
CY2022	mrns	Fixed Assets Written Off FixedAssetsWrittenOff	828000
CY2021	mrns	Fixed Assets Written Off FixedAssetsWrittenOff	243000
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	1169000
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-930000
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	930000
CY2022	mrns	Increase Decrease In Contract With Customer Refund Liability IncreaseDecreaseInContractWithCustomerRefundLiability	-22163000
CY2021	mrns	Increase Decrease In Contract With Customer Refund Liability IncreaseDecreaseInContractWithCustomerRefundLiability	22163000
CY2022	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	-17894000
CY2021	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	452000
CY2022	mrns	Increase Decrease In Prepaid Expense And Other Assets Noncurrent Assets Inventory And Accounts Receivable IncreaseDecreaseInPrepaidExpenseAndOtherAssetsNoncurrentAssetsInventoryAndAccountsReceivable	5577000
CY2021	mrns	Increase Decrease In Prepaid Expense And Other Assets Noncurrent Assets Inventory And Accounts Receivable IncreaseDecreaseInPrepaidExpenseAndOtherAssetsNoncurrentAssetsInventoryAndAccountsReceivable	853000
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3754000
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	7841000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-112886000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-55477000
CY2022	mrns	Proceeds From Sale Of Priority Review Voucher ProceedsFromSaleOfPriorityReviewVoucher	107375000
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	171000
CY2021	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	1474000
CY2021	mrns	Payments For Deposit And Property And Equipment PaymentsForDepositAndPropertyAndEquipment	1793000
CY2022	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	1774000
CY2021	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	1096000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	105772000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1415000
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1794000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1199000
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	28588000
CY2021	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	40259000
CY2022	mrns	Proceeds From Revenue Interest Financing Agreement Net Of Issuance Costs ProceedsFromRevenueInterestFinancingAgreementNetOfIssuanceCosts	29921000
CY2022	mrns	Payments Of Revenue Interest Financing Debt PaymentsOfRevenueInterestFinancingDebt	42000
CY2021	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	148000
CY2022	mrns	Proceeds From Equity Offerings Net ProceedsFromEquityOfferingsNet	64477000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	124738000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	41310000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	117624000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-15582000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	122927000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	138509000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	240551000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	122927000
CY2021	mrns	Contractual Exit Fee Included In Notes Payable ContractualExitFeeIncludedInNotesPayable	900000
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	22000
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	43000
CY2022	us-gaap	Interest Paid Net InterestPaidNet	7892000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	2032000
CY2022	mrns	Property And Equipment In Deposits Placed In Service PropertyAndEquipmentInDepositsPlacedInService	1664000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-19800000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-430500000
CY2022Q3	mrns	Proceeds From Sale Of Priority Review Voucher ProceedsFromSaleOfPriorityReviewVoucher	107400000
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from such estimates.</p>
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0
CY2022	mrns	Number Of Customers NumberOfCustomers	1
CY2022	mrns	Trade Receivable Payment Term TradeReceivablePaymentTerm	P30D
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.001
CY2022	mrns	Number Of Customers NumberOfCustomers	1
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13588000
CY2022Q4	mrns	Accrued Clinical Trial Expenses Current AccruedClinicalTrialExpensesCurrent	5700000
CY2022Q4	mrns	Prepaid Clinical Expenses PrepaidClinicalExpenses	3900000
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-19816000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-98776000
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39072599
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36697171
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.51
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.69
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7262195
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5679880
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5690000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3893000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1454000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1394000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4236000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2499000
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	300000
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	300000
CY2022Q4	us-gaap	Assets Held For Sale Not Part Of Disposal Group AssetsHeldForSaleNotPartOfDisposalGroup	700000
CY2021Q4	us-gaap	Assets Held For Sale Not Part Of Disposal Group AssetsHeldForSaleNotPartOfDisposalGroup	300000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2305000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	327000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1978000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	637000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1341000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1978000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13169000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7061000
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5830000
CY2022Q4	mrns	Clinical Trials And Drug Development Current ClinicalTrialsAndDrugDevelopmentCurrent	5725000
CY2021Q4	mrns	Clinical Trials And Drug Development Current ClinicalTrialsAndDrugDevelopmentCurrent	8217000
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1417000
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1311000
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	2445000
CY2022Q4	mrns	Third Party Commercial Expenses Current ThirdPartyCommercialExpensesCurrent	1880000
CY2022Q4	mrns	Lease Liability Short Term LeaseLiabilityShortTerm	637000
CY2021Q4	mrns	Lease Liability Short Term LeaseLiabilityShortTerm	556000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	371000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	293000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	19536000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	16207000
CY2022Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P78M
CY2022Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P60M
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P33M
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1300000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1700000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2000000.0
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2500000
CY2021	us-gaap	Lease Cost LeaseCost	600000
CY2022	us-gaap	Lease Cost LeaseCost	600000
CY2022Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.110
CY2021	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0
CY2022	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	823000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	840000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	642000
CY2022	mrns	Maximum Percentage Of Beneficial Ownership For Exercise Of Pre Funded Warrants MaximumPercentageOfBeneficialOwnershipForExerciseOfPreFundedWarrants	0.0999
CY2022	mrns	Maximum Percentage Increase Or Decrease Of Beneficial Ownership For Exercise Of Pre Funded Warrants MaximumPercentageIncreaseOrDecreaseOfBeneficialOwnershipForExerciseOfPreFundedWarrants	0.1999
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	75000000
CY2022Q4	mrns	Contractual Term Loan Exit Fees ContractualTermLoanExitFees	2003000
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	5985000
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	71018000
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	11250000
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	15000000
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	48750000
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	75000000
CY2022	mrns	Revenue Interest Financing Agreement Issuance Costs RevenueInterestFinancingAgreementIssuanceCosts	2600000
CY2022	mrns	Revenue Interest Financing Agreement Estimated Effective Annual Interest Rate RevenueInterestFinancingAgreementEstimatedEffectiveAnnualInterestRate	0.19
CY2022Q4	mrns	Revenue Interest Financing Agreements RevenueInterestFinancingAgreements	32500000
CY2022Q4	mrns	Revenue Interest Financing Agreement Issuance Costs RevenueInterestFinancingAgreementIssuanceCosts	2579000
CY2022Q4	mrns	Revenue Interest Financing Agreement Non Cash Interest Income Expense RevenueInterestFinancingAgreementNonCashInterestIncomeExpense	956000
CY2022Q4	mrns	Revenue Interest Financing Agreement Amortization Of Debt Discount RevenueInterestFinancingAgreementAmortizationOfDebtDiscount	42000
CY2022Q4	mrns	Revenue Interest Financing Agreement Payments RevenueInterestFinancingAgreementPayments	-42000
CY2022Q4	mrns	Revenue Interest Financing Agreements RevenueInterestFinancingAgreements	30877000
CY2022Q4	mrns	Revenue Interest Financing Payable Current RevenueInterestFinancingPayableCurrent	1020000
CY2022Q4	mrns	Revenue Interest Financing Payable Net Of Deferred Offering Costs Noncurrent RevenueInterestFinancingPayableNetOfDeferredOfferingCostsNoncurrent	29857000
CY2021Q1	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.03
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	1000000.0
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	700000
CY2022	mrns	Defined Contribution Plan Employer Contribution Vesting Period DefinedContributionPlanEmployerContributionVestingPeriod	P4Y
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	2445000
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	944000
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	3389000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3389000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-16427000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-98776000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-16427000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-98776000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	58056000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	81719000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	124000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	272000
CY2022Q4	mrns	Deferred Tax Assets Amortization DeferredTaxAssetsAmortization	454000
CY2021Q4	mrns	Deferred Tax Assets Amortization DeferredTaxAssetsAmortization	251000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	8091000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	5944000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	30627000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	16162000
CY2022Q4	mrns	Deferred Tax Asset Lease Liability DeferredTaxAssetLeaseLiability	440000
CY2021Q4	mrns	Deferred Tax Asset Lease Liability DeferredTaxAssetLeaseLiability	610000
CY2022Q4	mrns	Deferred Tax Assets Capitalized Research And Development Expenses DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses	22382000
CY2021Q4	mrns	Deferred Tax Assets Capitalized Research And Development Expenses DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses	11437000
CY2022Q4	mrns	Deferred Tax Assets Royalty Or Deferred Revenue DeferredTaxAssetsRoyaltyOrDeferredRevenue	3781000
CY2022Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	94000
CY2021Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	6000
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	64000
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	3000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	124113000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	116404000
CY2022Q4	mrns	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	291000
CY2021Q4	mrns	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	399000
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	224000
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	99000
CY2022Q4	us-gaap	Deferred Tax Liabilities Tax Deferred Income DeferredTaxLiabilitiesTaxDeferredIncome	192000
CY2021Q4	us-gaap	Deferred Tax Liabilities Tax Deferred Income DeferredTaxLiabilitiesTaxDeferredIncome	212000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	707000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	710000
CY2022Q4	mrns	Deferred Tax Assets Liabilities Before Valuation Allowance DeferredTaxAssetsLiabilitiesBeforeValuationAllowance	123406000
CY2021Q4	mrns	Deferred Tax Assets Liabilities Before Valuation Allowance DeferredTaxAssetsLiabilitiesBeforeValuationAllowance	115694000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	123406000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	115694000
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	7700000
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	23600000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2021Q4	mrns	Liability For Uncertain Tax Positions LiabilityForUncertainTaxPositions	0
CY2022Q4	mrns	Liability For Uncertain Tax Positions LiabilityForUncertainTaxPositions	0
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.026
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.007
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.090
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.022
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.881
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.043
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.595
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.028
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.057
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.470
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.240
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Other EffectiveIncomeTaxRateReconciliationTaxCreditsOther	-0.059
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.206
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001558370-23-003305-index-headers.html	Edgar Link	pending
0001558370-23-003305-index.html	Edgar Link	pending
0001558370-23-003305.txt	Edgar Link	pending
0001558370-23-003305-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mrns-20221231.xsd	Edgar Link	pending
mrns-20221231x10k.htm	Edgar Link	pending
mrns-20221231x10k001.jpg	Edgar Link	pending
mrns-20221231x10k004.jpg	Edgar Link	pending
mrns-20221231xex10d42.htm	Edgar Link	pending
mrns-20221231xex10d5.htm	Edgar Link	pending
mrns-20221231xex10d7.htm	Edgar Link	pending
mrns-20221231xex21.htm	Edgar Link	pending
mrns-20221231xex23d1.htm	Edgar Link	pending
mrns-20221231xex31d1.htm	Edgar Link	pending
mrns-20221231xex31d2.htm	Edgar Link	pending
mrns-20221231xex32d1.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
mrns-20221231_cal.xml	Edgar Link	unprocessable
mrns-20221231_def.xml	Edgar Link	unprocessable
mrns-20221231_lab.xml	Edgar Link	unprocessable
mrns-20221231_pre.xml	Edgar Link	unprocessable
mrns-20221231x10k_htm.xml	Edgar Link	completed
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MRNS
MARINUS PHARMACEUTICALS, INC. Stock $mrns

2023 Q1 Form 10-K Financial Statement

#000155837023003305 Filed on March 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MRNS MARINUS PHARMACEUTICALS, INC. Stock $mrns

2023 Q1 Form 10-K Financial Statement

#000155837023003305 Filed on March 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MRNS
MARINUS PHARMACEUTICALS, INC. Stock $mrns